No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease
Joseph A. Murray(Johns Hopkins University), Richard A. Krause, Peter H.R. Green(Columbia University Irving Medical Center), John J. Condemi(Baylor College of Medicine), Christopher E. Devereaux, Anna Basile(Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona), Jonathan Corren(California Allergy and Asthma Medical Group), Richard N. Fedorak(University of Alberta), Craig Ennis, Lucinda A. Harris, Stefanie Freeman, P Bercík, Valerie Byrnes, K. Jagarlamundi(Tampere University Hospital), C. Behrend, Kiren Gill(Tampere University Hospital), Vishal S. Chandan(University of California, Irvine), Annette Marcantonio, Allan Coates, Keith Friedenberg, Ronald Kotfila, Michael J. Goldstein(Hackensack University Medical Center), Clinton N. Corder, Shoab Ansari, B. Freilich(Kansas City Research Institute), Brian Bressler(University of British Columbia), A. Collatrella, Ronald Fogel(Henry Ford Health System), G. James, Markku Mäki(Tampere University), Alan B. Goldsobel, Robert Hardi, Bradley E. Chipps, Mustafa Kaplan, Ciarán P. Kelly(Met Éireann), Daniel C. Adelman(University of California, San Francisco), Taddese Desta, Anette Knoll(Statistisches Bundesamt), Daniel J. Geenen, J. Goldstein(Mayo Clinic), JERZY KIRSTEIN(Mayo Clinic), R.J. Holmes, Mark T. DeMeo, K Ayub(Tampere University Hospital), Glenn L. Gordon, Tsung‐Teh Wu(Analatom (United States)), Marsha Dupree, V. Cheekati, C. Martin Curtis, Anthony J. DiMarino(Thomas Jefferson University)
Cited by 137
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
|Clinical Infectious Diseases|2017|2.7k
Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis
|Clinical Gastroenterology and Hepatology|2018|1.7k
Lebrikizumab Treatment in Adults with Asthma
|New England Journal of Medicine|2011|1.5k